IS2662B - Mótefni sem blokka prótínið Cripto og notkun þeirra - Google Patents

Mótefni sem blokka prótínið Cripto og notkun þeirra

Info

Publication number
IS2662B
IS2662B IS6999A IS6999A IS2662B IS 2662 B IS2662 B IS 2662B IS 6999 A IS6999 A IS 6999A IS 6999 A IS6999 A IS 6999A IS 2662 B IS2662 B IS 2662B
Authority
IS
Iceland
Prior art keywords
antibodies
block
cripto protein
cripto
protein
Prior art date
Application number
IS6999A
Other languages
English (en)
Icelandic (is)
Other versions
IS6999A (is
Inventor
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2662(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of IS6999A publication Critical patent/IS6999A/is
Publication of IS2662B publication Critical patent/IS2662B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS6999A 2001-04-26 2003-10-24 Mótefni sem blokka prótínið Cripto og notkun þeirra IS2662B (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US29302001P 2001-05-17 2001-05-17
US30109101P 2001-06-26 2001-06-26
US36700202P 2002-03-22 2002-03-22
PCT/US2002/011950 WO2002088170A2 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof

Publications (2)

Publication Number Publication Date
IS6999A IS6999A (is) 2003-10-24
IS2662B true IS2662B (is) 2010-08-15

Family

ID=27501437

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6999A IS2662B (is) 2001-04-26 2003-10-24 Mótefni sem blokka prótínið Cripto og notkun þeirra

Country Status (33)

Country Link
US (6) US7531174B2 (cg-RX-API-DMAC7.html)
EP (3) EP2316486A3 (cg-RX-API-DMAC7.html)
JP (4) JP4307845B2 (cg-RX-API-DMAC7.html)
KR (1) KR100592357B1 (cg-RX-API-DMAC7.html)
CN (1) CN100352501C (cg-RX-API-DMAC7.html)
AR (3) AR037223A1 (cg-RX-API-DMAC7.html)
AT (2) ATE420659T1 (cg-RX-API-DMAC7.html)
BG (1) BG108363A (cg-RX-API-DMAC7.html)
BR (1) BR0209254A (cg-RX-API-DMAC7.html)
CA (2) CA2443840C (cg-RX-API-DMAC7.html)
CL (1) CL2009002199A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108960T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033208A3 (cg-RX-API-DMAC7.html)
DE (1) DE60230868D1 (cg-RX-API-DMAC7.html)
DK (1) DK1390389T3 (cg-RX-API-DMAC7.html)
EA (1) EA007469B1 (cg-RX-API-DMAC7.html)
EE (1) EE200300528A (cg-RX-API-DMAC7.html)
ES (1) ES2321065T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20074091B (cg-RX-API-DMAC7.html)
HU (1) HUP0501113A3 (cg-RX-API-DMAC7.html)
IS (1) IS2662B (cg-RX-API-DMAC7.html)
MX (1) MXPA03009797A (cg-RX-API-DMAC7.html)
MY (2) MY157382A (cg-RX-API-DMAC7.html)
NO (1) NO20034805L (cg-RX-API-DMAC7.html)
NZ (1) NZ566268A (cg-RX-API-DMAC7.html)
PL (1) PL207087B1 (cg-RX-API-DMAC7.html)
PT (1) PT1390389E (cg-RX-API-DMAC7.html)
RS (2) RS20110024A (cg-RX-API-DMAC7.html)
SG (1) SG157951A1 (cg-RX-API-DMAC7.html)
SI (1) SI1390389T1 (cg-RX-API-DMAC7.html)
SK (1) SK14432003A3 (cg-RX-API-DMAC7.html)
TR (1) TR200301846T2 (cg-RX-API-DMAC7.html)
WO (1) WO2002088170A2 (cg-RX-API-DMAC7.html)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
CA2443840C (en) 2001-04-26 2010-10-26 Biogen, Inc. Cripto blocking antibodies and uses thereof
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
AU2004252170B2 (en) 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP2135952A3 (en) 2003-09-15 2010-09-29 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
KR20070100346A (ko) * 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2412383A1 (en) * 2006-07-28 2012-02-01 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CN101970001A (zh) * 2007-06-01 2011-02-09 比奥根艾迪克Ma公司 Cripto结合分子
EP2279414A4 (en) * 2008-04-21 2011-06-29 Merck Sharp & Dohme PANCREATIC BETA CELL MASSE BIOMARKERS
WO2010054328A2 (en) * 2008-11-07 2010-05-14 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
RS52983B (sr) 2010-04-15 2014-02-28 Spirogen Sárl Pirolobenzodiazepini i njihovi konjugati
CN119552249A (zh) 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
SI2750713T1 (sl) 2011-10-14 2016-01-29 Medimmune Limited Pirolobenzodiazepini in njihovi konjugati
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
BR112015014669B1 (pt) 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6721507B2 (ja) 2013-12-23 2020-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20160074527A1 (en) 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2016083468A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
AU2016245328A1 (en) * 2015-04-07 2017-10-12 Paranta Biosciences Limited A method of treating neoplasias
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
KR102583006B1 (ko) 2016-12-21 2023-09-27 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
PL3612234T3 (pl) 2017-04-20 2024-09-02 Adc Therapeutics Sa Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
SMT202200225T1 (it) 2017-08-18 2022-07-21 Medimmune Ltd Coniugati di pirrolobenzodiazepina
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3115110A1 (en) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
JP7570329B2 (ja) 2018-12-13 2024-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AU2020242747B2 (en) 2019-03-15 2025-09-18 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2025132978A1 (en) * 2023-12-19 2025-06-26 BioNTech SE Cfc1 binding molecule
WO2025132976A1 (en) * 2023-12-19 2025-06-26 BioNTech SE Cfc1 binding molecule

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
KR20000015893A (ko) * 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
WO2000063693A1 (en) * 1999-04-20 2000-10-26 Kokolus William J Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
WO2001064754A1 (en) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Gene recombinant antibody and its fragment
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
JP2004524810A (ja) 2000-09-18 2004-08-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ変異体およびその使用
JP3821779B2 (ja) 2001-01-26 2006-09-13 アメリカ合衆国 Ｃｒｉｐｔｏ−１の検出及び定量
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
CA2443840C (en) 2001-04-26 2010-10-26 Biogen, Inc. Cripto blocking antibodies and uses thereof
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
KR101008758B1 (ko) * 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20040014690A1 (en) 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
EP2135952A3 (en) * 2003-09-15 2010-09-29 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
KR20070100346A (ko) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
JP2009535033A (ja) 2006-04-28 2009-10-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ−３の検出のための組成物および方法

Also Published As

Publication number Publication date
BG108363A (bg) 2004-09-30
KR20040028744A (ko) 2004-04-03
US7888052B2 (en) 2011-02-15
US8003763B2 (en) 2011-08-23
WO2002088170A3 (en) 2003-12-24
US20080166341A1 (en) 2008-07-10
HK1058935A1 (en) 2004-06-11
TR200301846T2 (tr) 2006-10-26
MY150237A (en) 2013-12-31
ES2321065T3 (es) 2009-06-02
SI1390389T1 (sl) 2009-06-30
CL2009002199A1 (es) 2010-05-07
EP1974749A1 (en) 2008-10-01
PT1390389E (pt) 2009-04-03
JP2009108100A (ja) 2009-05-21
MY157382A (en) 2016-06-15
WO2002088170A2 (en) 2002-11-07
US20090285818A1 (en) 2009-11-19
KR100592357B1 (ko) 2006-06-22
AR072554A2 (es) 2010-09-08
JP2004534020A (ja) 2004-11-11
HUP0501113A2 (en) 2007-05-02
JP4307845B2 (ja) 2009-08-05
SK14432003A3 (sk) 2004-07-07
SG157951A1 (en) 2010-01-29
CN1606453A (zh) 2005-04-13
RS51635B (sr) 2011-08-31
EP1390389A4 (en) 2004-09-22
EE200300528A (et) 2004-08-16
YU84903A (sh) 2006-05-25
PL373513A1 (en) 2005-09-05
JP2005314436A (ja) 2005-11-10
BR0209254A (pt) 2006-10-03
EP1390389B1 (en) 2009-01-14
IS6999A (is) 2003-10-24
AR037223A1 (es) 2004-11-03
EA007469B1 (ru) 2006-10-27
HUP0501113A3 (en) 2007-12-28
CA2443840A1 (en) 2002-11-07
EP2316486A3 (en) 2011-09-07
US7674462B2 (en) 2010-03-09
CA2715570A1 (en) 2002-11-07
EP1390389A2 (en) 2004-02-25
US20120195912A1 (en) 2012-08-02
US20090286265A1 (en) 2009-11-19
ATE420659T1 (de) 2009-01-15
NO20034805L (no) 2003-12-23
ATE533508T1 (de) 2011-12-15
EP1974749B1 (en) 2011-11-16
RS20110024A (sr) 2011-08-31
NZ566268A (en) 2009-09-25
DK1390389T3 (da) 2009-04-20
CZ20033208A3 (en) 2004-03-17
EP2316486A2 (en) 2011-05-04
GEP20074091B (en) 2007-04-25
US20100202962A1 (en) 2010-08-12
JP4575983B2 (ja) 2010-11-04
CA2443840C (en) 2010-10-26
US7531174B2 (en) 2009-05-12
US20040146940A1 (en) 2004-07-29
PL207087B1 (pl) 2010-10-29
US8673303B2 (en) 2014-03-18
DE60230868D1 (de) 2009-03-05
CY1108960T1 (el) 2014-07-02
NO20034805D0 (no) 2003-10-27
AR077759A2 (es) 2011-09-21
CN100352501C (zh) 2007-12-05
MXPA03009797A (es) 2004-01-29
JP2010163438A (ja) 2010-07-29
EA200301158A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
IS2662B (is) Mótefni sem blokka prótínið Cripto og notkun þeirra
EP1412378A4 (en) APTAMERES AND ANTIAPTAMERS
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
FI20010157L (fi) Probioottiyhdistelmä
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
DE60212600D1 (de) Audiocodierung und decodierung
NO20033418L (no) Immunregulatoriske antistoffer og anvendelse derav
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
DK1746375T3 (da) Oxygendrevet forbrændingssystem og anvendelser deraf
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
ITRM20020264A0 (it) Articolo assorbente e procedimento per la sua fabbricazione.
FI20010694A0 (fi) Implantti
DE60220486D1 (de) Zurückschaltungseinrichtung und Zurückschaltungsverfahren
EP1351388A4 (en) PHASE SLIDER AND MULTIBIT PHASE SLIDER
DE60223675D1 (de) Homogenisiervorrichtung
DE60144265D1 (de) Halbleiterbauelement und dessen herstelllung
NO20041219L (no) Manipulersikkert festeband
AU2002357934A8 (en) Humanized lactoferrin and uses thereof
DE50210561D1 (de) Sitz- und/oder liegemöbel
DE60205008D1 (de) Kettelverfahren und -vorrichtung
IS8914A (is) Mótefni sem blokka prótínið Cripto og notkun þeirra
DE60219418T8 (de) Silanylphenole und -naphthole
DE50203221D1 (de) Signalisierungsverfahren und -anordnung